Relief Therapeutics Holding AG, a clinical stage biotechnology company, engages in developing treatment solutions for indications related to diabetic complications and respiratory diseases. The company is developing aviptadil, which has completed Phase II clinical trial for the treatment of sarcoidosis, an orphan pulmonary disease, as well as pulmonary hypertension; and atexakin alfa that has completed Phase I clinical trial to treat peripheral diabetic neuropathy. Relief Therapeutics Holding AG is based in Geneva, Switzerland.
RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells
- Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites
- Aviptadil is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes
- RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol
DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.